carfilzomib + carboplatin + etoposide

**Carfilzomib + carboplatin + etoposide** is a combination chemotherapy regimen under investigation, primarily in hematologic and solid tumors. Carfilzomib is a selective, irreversible inhibitor of the 20S proteasome’s chymotrypsin-like activity, leading to disruption of protein homeostasis and induction of apoptosis in malignant cells. Carboplatin, a platinum-based chemotherapeutic, forms DNA intrastrand and interstrand cross-links, preventing DNA replication and transcription. Etoposide is a topoisomerase II inhibitor that induces DNA strand breaks and apoptosis. This combination has been studied in phase 1b trials for extensive-stage small cell lung cancer (ES-SCLC) and diffuse large B-cell lymphoma (DLBCL), showing anti-tumor activity and a safety profile consistent with known agent toxicities[1][4][6].